Therefore, ibrutinib-mediated inhibition of ITK can robustly enhance anti-tumor immune responses by favoring TH1 differentiation and promoting the effector functions of CD8 cytotoxic T cells (96). The gene discussed is CD8A; the disease is neoplasm.